AffiliationCRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. email@example.com
MetadataShow full item record
AbstractRecent studies have shown that paclitaxel (Taxol); Bristol-Myers Squibb Co., Princeton, NJ) is an active agent in the treatment of advanced non-small cell lung cancer (NSCLC). Early trials in patients with advanced NSCLC utilised a 24 h infusion schedule and reported objective tumour responses in 21 - 24% of patients. Shorter infusion schedules have equivalent efficacy, and combined results from 14 separate trials of single agent paclitaxel in advanced NSCLC show an overall tumour response rate of 26%. Alternative schedules of paclitaxel from the traditional regimen every three weeks are under active investigation, but it is premature to assess whether these will yield improved efficacy for patients with advanced NSCLC. A single multicentre randomised trial of paclitaxel versus best supportive care in advanced NSCLC showed a significant survival advantage for the chemotherapy arm. Two large randomised Phase III trials have shown that paclitaxel and cisplatin is modestly more effective than cisplatin and podophyllotoxin combinations. The addition of cisplatin or carboplatin to paclitaxel results in higher response rates than for each of the drugs as single agents, but it is unclear whether the combinations yield superior survival or quality of life compared to single agent paclitaxel, or to other paclitaxel-containing regimens.
CitationPaclitaxel: a hope for advanced non-small cell lung cancer? 1999, 8 (6):837-48 Expert Opin Investig Drugs
JournalExpert Opinion on Investigational Drugs
- Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions.
- Authors: Bunn PA Jr
- Issue date: 1997 Aug
- Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.
- Authors: Socinski MA
- Issue date: 1999
- Review of paclitaxel/carboplatin in advanced non-small cell lung cancer.
- Authors: Bonomi P
- Issue date: 1999 Feb
- [Treatment of the unresectable non small cell lung carcinoma].
- Authors: Spásová I
- Issue date: 2005
- Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.
- Authors: Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DH, Tucker RW, Mills GM, Gandara DR, Southwest Oncology Group Trial S0003.
- Issue date: 2005 Dec 20